BOSTON (TheStreet) -- Labor Day is over and Hurricane Earl is out to sea, which means Wall Street is returning to work in earnest for the last three months of the year.
To put everyone in the right mindset, I've compiled a "Back to School" guide covering the essential information biotech investors need to profit from what should be a very busy fall season.
Before we look ahead, take a quick look at the year to date. The Nasdaq Biotechnology Index (NBI), a market-cap weighted index of 125 stocks and the broadest measure of biotech sector performance, is essentially flat for the year compared to a 1% drop in the S&P 500 (see graph above).The Amex Biotechnology Index (BTK), which equal weights 20 stocks, is up 18% for the year, although the acquisitions of index stocks OSI Pharmaceuticals and Millipore, plus the surge in Genzyme (GENZ) shares due to the Sanofi-Aventis (SNY) takeover speculation, have skewed the index higher. The top-performing biotech/drug stock so far this year is Somaxon Pharmaceuticals (SOMX), up 245% through Sept. 2. Somaxon's stellar performance comes despite a fall in the stock's value from $10 in March to $4 in September. Somaxon wins, however, because shares traded for just a buck in January. Rounding out the top five stop biotech stock performers in 2010 to date are Radient Pharmaceuticals (RPC) (up 192%), Idenix Pharmaceuticals (IDIX) (up 176%), Prolor Biotech (PBTH) (up 155%) and Pharmacyclics (PCYC) (up 142%). (Stocks trading on the OTC or Pink Sheets were excluded.)
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV